LIDDS AB (publ) is a Swedish pharmaceutical company that focuses on developing innovative pharmaceutical products based on medical need and their proprietary drug delivery technology called NanoZolid®. This technology addresses the challenges associated with drug delivery, allowing for controlled, long-term release of drugs for up to six months. LIDDS can combine NanoZolid® with both small and large molecules, enabling the formulation of drugs for local administration. With their advanced drug delivery system, LIDDS aims to improve patient quality of life by providing personalized and sustained drug release.